Scholarlink

Purpose <p>To evaluate the in vitro drug sensitivity of patient-derived cancer organoids (PDCOs) established from residual samples from saline flushes (RSSF) collected during routine endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in patients with pancreatic cancer.</p> Methods <p>Organoids were cultured under mutation-selective conditions. IC<sub>50</sub> values for 5-fluorouracil (5-FU), SN-38, oxaliplatin, gemcitabine, and paclitaxel were calculated.</p> Results <p>PDCOs showed variable responses to the drugs. Exploratory quantitative analysis using ordinal sensitivity scoring and ROC curves (Area under the curve [AUC] up to 0.917) indicated that lower in vitro IC₅₀ scores tended to associate with clinical responders (PR/uPR) compared with non-responders (progressive or stable disease [PD/SD]).</p> Conclusions <p>This study demonstrated the feasibility and potential usefulness of in vitro drug sensitivity profiling of pancreatic cancer using RSSF-derived PDCOs. These findings represent the first step toward clinical application, and further validation in larger cohorts is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routine EUS-FNA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月21日

查看全文
  • Tomoya Ekawa,
  • Kenji Ikezawa,
  • Yoji Kukita,
  • Makiko Urabe,
  • Yugo Kai,
  • Ryoji Takada,
  • Takashi Akazawa,
  • Yu Mizote,
  • Kumiko Tatsumi,
  • Shigenori Nagata,
  • Hisataka Ogawa,
  • Shinichiro Hasegawa,
  • Hidenori Takahashi,
  • Kazuyoshi Ohkawa,
  • Hideaki Tahara

摘要

Purpose

To evaluate the in vitro drug sensitivity of patient-derived cancer organoids (PDCOs) established from residual samples from saline flushes (RSSF) collected during routine endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in patients with pancreatic cancer.

Methods

Organoids were cultured under mutation-selective conditions. IC50 values for 5-fluorouracil (5-FU), SN-38, oxaliplatin, gemcitabine, and paclitaxel were calculated.

Results

PDCOs showed variable responses to the drugs. Exploratory quantitative analysis using ordinal sensitivity scoring and ROC curves (Area under the curve [AUC] up to 0.917) indicated that lower in vitro IC₅₀ scores tended to associate with clinical responders (PR/uPR) compared with non-responders (progressive or stable disease [PD/SD]).

Conclusions

This study demonstrated the feasibility and potential usefulness of in vitro drug sensitivity profiling of pancreatic cancer using RSSF-derived PDCOs. These findings represent the first step toward clinical application, and further validation in larger cohorts is warranted.